Tevard Biosciences Announces Publication of Preclinical Research Supporting Engineered Suppressor tRNAs for Duchenne Muscular Dystrophy

Boston, Massachusetts--(Newsfile Corp. - September 9, 2026) - Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today highlighted the publication of research conducted by scientists at Tevard Biosciences, Johns Hopkins University, MIT, and the Whitehead Institute for Biomedical Research in Science Advances. The paper, entitled "Engineering suppressor tRNAs for effective treatment of Duchenne Muscular Dystrophy,"...

2026-09-09 2:27 PM EDT